nach oben

Current Cardiology Reports

Erschienen in:

01.02.2018 | Structural Heart Disease (RJ Siegel and NC Wunderlich, Section Editors)

Heart Failure Interventions Targeting Impaired Left Ventricles in Structural Heart Disease

verfasst von: Mitsunobu Kitamura, Tobias Schmidt, Karl-Heinz Kuck, Christian Frerker

Erschienen in: Current Cardiology Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Interventional techniques have been developed for a wide spectrum of mechanisms of heart failure (HF), especially in valvular heart disease and cardiomyopathies (ischaemic cardiomyopathy and hypertrophic cardiomyopathy). In this article, we review recent reports on catheter interventions to treat patients with HF.

Recent Findings

Direct modification using the Parachute device and the REVIVENT-TC device for patients with impaired left ventricle with large infarct scars improves geometry and haemodynamic efficiency, resulting in a reduction of HF symptoms. Interatrial shunt therapy improves symptoms and quality of life in HF patients. Uniquely, left ventricular outflow tract obstruction has also been targeted in patients with transcatheter mitral valve implantation.

Summary

For advanced stage HF patients with prohibitively high surgical risk, emerging transcatheter interventions make it possible to modify life-limiting symptoms. Further results on HF interventions are expected from ongoing clinical trials.

Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002;106(18):2351–7. https://doi.org/10.1161/01.CIR.0000036014.90197.FA.CrossRefPubMed

Savoye C, Equine O, Tricot O, Nugue O, Segrestin B, Sautiere K, et al. Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group). Am J Cardiol. 2006;98(9):1144–9. https://doi.org/10.1016/j.amjcard.2006.06.011.CrossRefPubMed

•• Costa MA, Mazzaferri EL Jr, Sievert H, Abraham WT. Percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure: three-year outcomes of the PARACHUTE first-in-human study. Circ Heart Fail. 2014;7(5):752–8. This is the first human study of a parachute device. CrossRefPubMed

•• Thomas M, Nienaber CA, Ince H, Erglis A, Vukcevic V, Schafer U, et al. Percutaneous ventricular restoration (PVR) therapy using the parachute device in 100 subjects with ischaemic dilated heart failure: one-year primary endpoint results of PARACHUTE III, a European trial. EuroIntervention. 2015;11(6):710–7. This report provides the results from the largest multicenter study of parachute device. CrossRefPubMed

Del Trigo M, Bergeron S, Bernier M, Amat-Santos IJ, Puri R, Campelo-Parada F, et al. Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study. Lancet. 2016;387(10025):1290–7. https://doi.org/10.1016/S0140-6736(16)00585-7.CrossRefPubMed

• Schmidt T, Frerker C, Thielsen T, Dotz I, Wohlmuth P, Kuck KH, et al. New evidence for favourable effects on haemodynamics and ventricular performance after parachute((R)) implantation in humans. Eur J Heart Fail. 2014;16(10):1112–9. This study descrives the effects of parachute device implantation on haemodynamics. CrossRefPubMed

Schäfer U, Lubos E, Deuschl F, Schofer N, Grahn H, Conradi L, et al. Transseptal and transmitral parachute(R) implantation in conjunction with “MitraClipping”. EuroIntervention. 2015;11(6):673–81. https://doi.org/10.4244/EIJY15M09_05.CrossRef

Costa MA, Pencina M, Nikolic S, Engels T, Templin B, Abraham WT. The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles. Am Heart J. 2013;165(4):531–6. https://doi.org/10.1016/j.ahj.2012.12.022.CrossRefPubMed

Cooley DA. Ventricular endoaneurysmorrhaphy: a simplified repair for extensive postinfarction aneurysm. J Card Surg. 1989;4(3):200–5. https://doi.org/10.1111/j.1540-8191.1989.tb00282.x.CrossRefPubMed

10.

Dor V, Saab M, Coste P, Kornaszewska M, Montiglio F. Left ventricular aneurysm: a new surgical approach. Thorac Cardiovasc Surg. 1989;37(1):11–9. https://doi.org/10.1055/s-2007-1013899.CrossRefPubMed

11.

Athanasuleas CL, Stanley AW Jr, Buckberg GD, Dor V, DiDonato M, Blackstone EH. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. RESTORE group Reconstructive Endoventricular Surgery, returning Torsion Original Radius Elliptical Shape to the LV. J Am Coll Cardiol. 2001;37(5):1199–209.CrossRefPubMed

12.

Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360(17):1705–17. https://doi.org/10.1056/NEJMoa0900559.CrossRefPubMedPubMedCentral

13.

Yamaguchi A, Adachi H, Kawahito K, Murata S, Ino T. Left ventricular reconstruction benefits patients with dilated ischemic cardiomyopathy. Ann Thorac Surg. 2005;79(2):456–61. https://doi.org/10.1016/j.athoracsur.2004.07.045.CrossRefPubMed

14.

Athanasuleas CL, Buckberg GD, Stanley AW, Siler W, Dor V, DiDonato M, et al. Surgical ventricular restoration: the RESTORE group experience. Heart Fail Rev. 2004;9(4):287–97. https://doi.org/10.1007/s10741-005-6805-4.CrossRefPubMed

15.

Michler RE, Rouleau JL, Al-Khalidi HR, Bonow RO, Pellikka PA, Pohost GM, et al. Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg. 2013;146(5):1139–45 e6. https://doi.org/10.1016/j.jtcvs.2012.09.007.CrossRefPubMed

16.

•• Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2014;10(9):1024–94. This is the current ESC/EACTS guideline for myocardial revascularization. CrossRef

17.

•• Wechsler AS, Sadowski J, Kapelak B, Bartus K, Kalinauskas G, Rucinskas K, et al. Durability of epicardial ventricular restoration without ventriculotomy. Eur J Cardiothorac Surg. 2013;44(3):e189–92. https://doi.org/10.1093/ejcts/ezt292. discussion e92. This is the first report of epicardial ventricular restoration using the Revivent device. CrossRefPubMed

18.

Heeger CH, Frerker C, Hayashi K, Schmidt T, Mathew S, Sohns C, et al. Catheter ablation of frequent ventricular tachycardia after interventional left ventricular restoration with the revivent-transcatheter(TM)-system. Clin Case Rep. 2016;4(4):339–43. https://doi.org/10.1002/ccr3.512.CrossRefPubMedPubMedCentral

19.

Observational study to collect data on health improvements after mini-invasive operation with Revivent TC device to reshape the heart and reduce its volume: BioVentrix Registry Assessment of Ventricular Enhancement for the Revivent TC system (BRAVE-TC). https://doi.org/10.1186/ISRCTN89757315, 2016; URL http://www.isrctn.com/ISRCTN89757315.

20.

Sondergaard L, Reddy V, Kaye D, Malek F, Walton A, Mates M, et al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail. 2014;16(7):796–801. https://doi.org/10.1002/ejhf.111.CrossRefPubMed

21.

Malek F, Neuzil P, Gustafsson F, Kaye DM, Walton A, Mates M, et al. Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. Int J Cardiol. 2015;187:227–8. https://doi.org/10.1016/j.ijcard.2015.03.198.CrossRefPubMed

22.

Feldman T, Komtebedde J, Burkhoff D, Massaro J, Maurer MS, Leon MB, et al. Transcatheter interatrial shunt device for the treatment of heart failure: rationale and design of the randomized trial to REDUCE elevated left atrial pressure in heart failure (REDUCE LAP-HF I). Circ Heart Fail. 2016;9(7):e003025. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003025.CrossRefPubMed

23.

Hasenfuss G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet. 2016;387(10025):1298–304. https://doi.org/10.1016/S0140-6736(16)00704-2.CrossRefPubMed

24.

Kaye DM, Hasenfuss G, Neuzil P, Post MC, Doughty R, Trochu JN, et al. One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9(12):e003662. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003662.

25.

Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346(8969):211–4. https://doi.org/10.1016/S0140-6736(95)91267-3.CrossRefPubMed

26.

•• Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79. This is the current ESC guideline for hypertrophic cardiomyopathy. CrossRefPubMed

27.

•• Veselka J, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37(19):1517–23. This is the first report from the Euro-ASA registry, the largest multinational study cohort. CrossRefPubMed

28.

• Veselka J, Faber L, Liebregts M, Cooper R, Januska J, Krejci J, et al. Outcome of alcohol septal ablation in mildly symptomatic patients with hypertrophic obstructive cardiomyopathy: a long-term follow-up study based on the euro-alcohol septal ablation registry. J Am Heart Assoc. 2017;6(5). https://doi.org/10.1161/JAHA.117.005735. This report describes the results of alcohol septal ablation in mildly symptomatic patients with hypertrophic obstructive cardiomyopathy.

29.

• Liebregts M, Faber L, Jensen MK, Vriesendorp PA, Januska J, Krejci J, et al. Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2017;10(11):1134–43. This report describes the results of alcohol septal ablation in younger patients with hypertrophic obstructive cardiomyopathy. CrossRefPubMed

30.

• Schäfer U, Kreidel F, Frerker C. MitraClip implantation as a new treatment strategy against systolic anterior motion-induced outflow tract obstruction in hypertrophic obstructive cardiomyopathy. Heart Lung Circ. 2014;23(5):e131–5. This is the first report of MitraClip® therapy for hypertrophic obstructive cardiomyopathy. CrossRefPubMed

31.

Schäfer U, Frerker C, Thielsen T, Schewel D, Bader R, Kuck KH, et al. Targeting systolic anterior motion and left ventricular outflow tract obstruction in hypertrophic obstructed cardiomyopathy with a MitraClip. EuroIntervention. 2015;11(8):942–7. https://doi.org/10.4244/EIJY14M08_13.CrossRefPubMed

Titel: Heart Failure Interventions Targeting Impaired Left Ventricles in Structural Heart Disease
verfasst von: Mitsunobu Kitamura
Tobias Schmidt
Karl-Heinz Kuck
Christian Frerker
Publikationsdatum: 01.02.2018
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 2/2018
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-018-0950-6

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Heart Failure Interventions Targeting Impaired Left Ventricles in Structural Heart Disease